跳至主要内容
临床试验/EUCTR2018-000434-34-AT
EUCTR2018-000434-34-AT进行中(未招募)1 期

A Phase I/II, randomized, prospective, controlled, multi-center, open-label,two arm study evaluating the safety and preliminary efficacy of sFilm-FS incontrolling liver bleeding during elective surgery.

Sealantium Medical Ltd.0 个研究点目标入组 30 人开始时间: 2020年2月25日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • 1. Patients (males or females) aged = 18 years old.
  • 2. Patients requiring elective surgery in which liver
  • bleeding will be encountered..
  • 3. Hemoglobin = 8.0 g/dL within 24 hours prior to surgical procedure.
  • 4. Patients understanding the nature of the study and providing their informed consent prior to participation.
  • 5. Patients willing to participate in the study and able to attend the
  • visits and procedures foreseen by study protocol.
  • Intra-operative inclusion criteria:
  • 6. Patients with a target bleeding site (TBS) identified by the
  • Investigator during surgery in which liver bleeding will be
  • encountered.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 25
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 5

排除标准

  • 1. Patients having undergone a therapeutic surgical procedure within
  • 30 days from the study enrolment.
  • 2. Patients with a severe coagulopathy defined as INR > 2.0.
  • 3. Patients with platelet count <50,000 x109 PLT/L at the screening.
  • 4. Patients admitted to trauma surgery.
  • 5. Transplant patients due to fulminant hepatic failure.
  • 6. Patients with known or suspected allergy or hypersensitivity to
  • blood products or to one of the components of sFilm-FS or the
  • active-comparator.
  • 7. Patients with anesthesia risk judged to be higher than ASA3 by the
  • Investigator.
  • 8. Patients with at least one of the following concomitant conditions:
  • severe co-morbid conditions known to pose a high risk for surgery
  • and adequate recovery (i.e. liver cirrhosis with Child-Pugh score B
  • or C, cholestasis, heart diseases), immunodeficiency diseases, blood
  • clotting disorders, any conditions known to effect wound healing
  • (i.e. collagen vascular disease), known or current alcohol or drug
  • 9. Patients suffering from claustrophobia.
  • 10. Patients with implanted or embedded metal objects, prostheses,
  • pacemaker, or fragments in the head or body that would present a risk during the MRI scanning procedure or have worked with ferrous
  • metals either as a vocation or hobby or following trauma (i.e., sheet
  • metal workers, welders, or machinists) in such a way that might have
  • led to unknown, indwelling metal fragments that could cause injury if
  • they moved in response to placement in the magnetic field.
  • 11. Patients being treated with at least one of the following treatments:
  • antibiotic therapy for active infection, fibrin sealants, systemic
  • steroids or immunosuppressive agents.
  • 12. Patients who are participating or have participated in other clinical
  • studies within the 30 days before the study enrolment.
  • 13. Female patients who are pregnant or breast-feeding or who wish to become pregnant during the period of the clinical study and for three months later.
  • 14. Female patients of childbearing age (less than 24 months after the last menstrual cycle) who do not use adequate contraception. *
  • Intra-operative exclusion criteria:
  • 15. Patients identified with a TBS with major arterial bleeding requiring suture or mechanical ligation.
  • 16. Patients identified by the Investigator to have intra-operative
  • bleeding from large defects in large arteries or veins, requiring
  • 17. Patients identified by the Investigator to have intra-operative
  • findings that may preclude conduct of study procedure.
  • 18. Patients having an active local infection in the anatomic surgical area.
  • 19. Patients with occurrence of major intra-operative complications that require resuscitation or deviation from the planned surgical
  • 20. Patients with bleeding site in or near to foramina in bone.

研究者

相似试验